Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03614013
Other study ID # 1180173
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date July 4, 2018
Est. completion date March 31, 2021

Study information

Verified date August 2018
Source Pontificia Universidad Catolica de Chile
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This project seeks to analyze and define the mechanism (s) involved in the resistance to checkpoint therapy in metastatic GC patients. The investigators propose the use of a Next-Generation Sequencing (NGS) assay that involves 395 genes allowing us to define a specific molecular signature to characterize responder and non-responder patients to checkpoint therapy in combination with IHC analyses of specific factors. Such signature (s) could then be used to predict which individuals who might get the most benefit out of checkpoint therapy treatment. Analysis will be perfomed retrospectively using biopsies provided by mGC patients recruited at the Red de Salud UC treated with checkpoint therapy, the response of patients to treatment is evaluated by RECIST 1.1 criteria and thereby they are classified as "responders" or "non-responders".


Description:

In Chile, gastric cancer (GC) is the leading cause of cancer death, killing 17.8 in 100,000 people/year. Most GC cases are diagnosed at advance stage, indeed 70% of diagnosed patients are stage IV classified as metastatic GC (mGC). Median survival rates with standard chemotherapy is <6 months. In recent years the development of immune checkpoint inhibitors that activate a sustained T-cell response has revolutionized oncology treatments. Indeed, humanized monoclonal antibodies against the CTLA4 and PD1/PDL1 pathways treatments, a strategy commonly called "checkpoint therapy" has demonstrated effective against many malignancies. Despite this, a substantial percentage of patients (~60%) remain unresponsive or display non-significant clinical responses to these regimes. Previous studies suggest that cancer cells employ a variety of strategies to become resistant to these therapies, these can include: existence of genomic alterations in their "mutational landscape" that cause immune suppression, inhibition of the Interferon (IFN) gamma pathway (among others), upregulation of alternative immune checkpoints (other than CTLA4 or PD1/PDL1) and upregulation of the Indoleamine 2,3-DyOxygenase (IDO) enzyme.

HYPOTHESIS:

Metastatic GC patients, whose tumor microenvironment presents a specific mutational landscape, increased levels of alternative immune co-inhibitors and enhanced IDO expression, fail (determined by RECIST 1.1) in response to checkpoint therapy.

In order to validate this hypothesis, the investigators will:

1. Retrospectively collect samples derived from mGC patients who received checkpoint therapy and clinical data including RECIST 1.1 (Response Evaluation Criteria In Solid Tumors) to classify them as responders or non-responders to checkpoint therapy.

2. Obtain RNA/DNA samples from stored patient biopsies in order to perform a comprehensive analysis of mutational landscape using Next Generation Sequencing (NGS) methods.

3. Analyze tissue samples from patients by immunohistochemistry to evaluate expression of the IDO enzyme and the levels of alternative immune co-inhibitors.

Therefore, this proposal will use samples derived from mGC patients who received checkpoint therapy at the Cancer center of the Clinical Hospital at the Pontificia Universidad Catolica de Chile. Biopsies, paraffin embedded samples and full clinical history are available for analysis. The team of investigators is composed by both physicians (MD) and molecular biologists (PhD). Dr. Garrido and clinical coordinator Dr. Retamal will select patients, obtain cancer samples and perform correlations with treatment outcome and coordinate the immunohistochemistry. The laboratory of Dr. Owen (co-investigator in this proposal with Dr. Pinto) has vast experience in the field of molecular oncology and will perform the molecular analysis.

The overall goal of this proposal is to elucidate the molecular mechanism(s) involved in the resistance to CTLA4/PD1/PDL1 targeted checkpoint therapy in mGC patients. The relevance lies in the high prevalence and mortality rates of this disease in Chile. Finally, its significance stems from the potential discovery and characterization diagnostic companion biomarkers that could allow stratification in order to identify mGC patients that could get the most benefit from checkpoint therapy regimes.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 50
Est. completion date March 31, 2021
Est. primary completion date June 30, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Chilean residents, male or female >18 yr-old

- Histologically confirmed metastatic gastric cancer

- Received immunotherapy using checkpoint inhibitors with clinical followup for at least 6 weeks

- Patients with paraffin samples or biopsies obtained form primary tumor

- Able to speak and understand Spanish and sign a written informed consent form

Exclusion Criteria:

- Patients without clinical records or no paraffin or biopsy sample

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Immunotherapy responders/non-responders
paraffin samples will be collected retrospectively along with clinical data

Locations

Country Name City State
Chile Centro de Cancer UC CHRISTUS Santiago

Sponsors (2)

Lead Sponsor Collaborator
Pontificia Universidad Catolica de Chile Fondo Nacional de Desarrollo Científico y Tecnológico, Chile

Country where clinical trial is conducted

Chile, 

Outcome

Type Measure Description Time frame Safety issue
Primary Survival Overall survival 3-12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04618809 - Improving the Approach to and Management of the Older Patient With Metastatic Gastric Cancer N/A
Recruiting NCT02668380 - An Open Label, Prospective, Multicentre, Non-interventional Study of Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer N/A
Completed NCT03121807 - Home Parenteral Nutrition for Malnourished Unresectable Stage IV Gastric Cancer N/A
Recruiting NCT04358354 - Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer Phase 3
Completed NCT01099527 - A Trial of RAD001/Capecitabine in Refractory Gastric Cancer Phase 1/Phase 2
Completed NCT00253370 - Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer Phase 2
Recruiting NCT02002195 - Modified Folinic Acid-Fluorouracil-Oxaliplatin Regimen + Capecitabine for Elderly With Metastatic Gastric Cancer
Recruiting NCT06008925 - Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer Phase 1/Phase 2
Recruiting NCT05714124 - Liver Embolization Approaches for Tumor Management
Recruiting NCT02855788 - Metronomic Chemotherapy in Advanced Gastric Cancer Phase 2
Recruiting NCT03154983 - The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer Phase 2
Not yet recruiting NCT04263870 - Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction Phase 2
Active, not recruiting NCT01359397 - Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer Phase 2
Recruiting NCT04739202 - Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) Phase 2
Completed NCT03409848 - Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma Phase 2
Recruiting NCT05859477 - Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer Phase 2
Recruiting NCT05955833 - 89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study Phase 1
Terminated NCT01528501 - Histone Deacetylases - Gastric Cancer (HDAC-GaCa-2008) Phase 2
Completed NCT03751761 - GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study Phase 1/Phase 2
Recruiting NCT05024812 - Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Phase 1/Phase 2